Teysuno (gimeracil/oteracil/tegafur)

P1/2, N=57, Not yet recruiting, Asan Medical Center

P=N/A, N=200, Enrolling by invitation, Helsinki University Central Hospital | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2020 --> Dec 2027

P2, N=110, Not yet recruiting, Qilu Hospital of Shandong University

A total of 21 patients with advanced HER2-negative GC, who had progressed after receiving standard first-line regimens [tegafur, gimeracil and oteracil potassium capsules (S-1) or capecitabine plus oxaliplatin], were selected. The present study retrospectively analyzed the new second-line approach of PD-1 inhibitor combined with taxanes for HER2 negative GC which effectively improved patient PFS and OS compared with single-agent chemotherapy. The expression levels of Ki67 and the tumor marker-negative status possess potential clinical value in monitoring prognosis and guiding future individualized use of chemotherapy combined with immunotherapy.

Eligible patients will be registered and receive three cycles of oxaliplatin and S-1 (SOX) regimen in combination with cadonilimab...The results of the study may provide more evidence for neoadjuvant immunotherapy combined with chemotherapy in locally advanced G/GOJ adenocarcinoma. ClinicalTrials.gov, NCT05948449.

After Oxaliplatin combined with S-1 regimen, the effect was up to PR...The combined application of S-1 and Apatinib in gastric cancer maintenance therapy deserves further study. Maintenance therapy for gastric cancer has attracted wide attention, and more large-scale clinical research is under way.

P3, N=29, Terminated, Peking University Cancer Hospital & Institute | N=564 --> 29 | Recruiting --> Terminated; The number of patients enrolled was much less than expected

We started a combination chemotherapy of tegafur-gimeracil-oteracil potassium (TS-1) and docetaxel. After four cycles of the pembrolizumab treatment, a CT scan showed further shrinkage in most of the lymph node metastases. As far as we know, the present patient is the first case of advanced EMPD with response to pembrolizumab monotherapy.

P1, N=120, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting

The combined therapy of APS and GS improved the recent efficacy and long-term survival of patients with pancreatic cancer and alleviated chemotherapy-induced immune suppression and adverse reactions.

We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.

P2, N=80, Not yet recruiting, Ruijin Hospital

ERCC1 mRNA is an independent prognostic factor and predictive marker that can be used to guide the addition of docetaxel. The SNPs of ERCC1 and GSTP1 could be also prognostic or predictive factors.

The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies: S-1 plus cisplatin (SP) and S-1 plus docetaxel (DS)...The nProfiler1 assay offers valuable insights into the prognosis and efficacy of adjuvant chemotherapy based on fluorouracil plus platinum doublet regimens but not docetaxel-containing regimens. Further validation with larger patient cohorts and different regimens is warranted.

P2, N=20, Recruiting, Jiangsu Province Hospital; Jiangsu Province Hospital

P2, N=400, Recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

P3, N=738, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2024 --> Sep 2025

In the first-line treatment of HER2-positive advanced gastric cancer, inetetamab and trastuzumab showed comparable efficacy. The inetetamab group showed superior PFS, and both groups had good safety.

P2/3, N=206, Not yet recruiting, Sun Yat-sen University

P2, N=30, Recruiting, Anhui Provincial Hospital

P2, N=56, Recruiting, Sun Yat-sen University

This work supports the role of toxic 5-FU metabolites generated by dihydropyrimidine dehydrogenase in the occurrence of ischemic cardiopathy among patients with gastric cancer using capecitabine.

The Dokkyo study confirmed the results observed in the Ehime study. Consequently, an increased postoperative CAR value appeared as a universal applicable marker for the risk factor of AE-related S-1 non-completion after curative surgery for patients with PC.

After three cycles of S-1, oxaliplatin, and trastuzumab, the primary tumor and metastases shrank markedly...He has been recurrence-free for seven months postoperatively. The present case demonstrated the efficacy of trastuzumab-containing chemotherapy followed by conversion surgery in a patient with HER2-positive, MSI-H, advanced gastric cancer.

These patients are scheduled to undergo a treatment comprising preoperative chemotherapy with paclitaxel, oxaliplatin and S-1, followed by D2 gastrectomy, and concluding with postoperative treatments that include prophylactic intraperitoneal chemotherapy. The study's primary objective is to evaluate the 3-year peritoneal recurrence rate. Secondary objectives are to assess the 3-year disease-free survival, 3-year overall survival and to monitor the adverse events.Clinical trial registration number: ChiCTR2400083253 (https://www.chictr.org.cn).

P1/2, N=40, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting

We report a patient with highly advanced gastric cancer with peritoneal dissemination, which worsened during second-line therapy and was successfully treated with gastrectomy after nivolumab administration as a third-line therapy. MSI-high gastric cancer is a target that should be actively considered for the administration of ICIs, such as nivolumab, and multidisciplinary treatment combined with chemotherapy and gastrectomy, including conversion surgery, can lead to patients' long-term survival.

P1, N=10, Completed, Beijing YouAn Hospital | Unknown status --> Completed | N=18 --> 10

P=N/A, N=30, Recruiting, First affiliated hospital of Soochow university; First affiliated hospital of Soochow university

P3, N=278, Recruiting, Henan Cancer Hospital; Henan Cancer Hospital

P2, N=60, Not yet recruiting, China Medical University Hospital

P2, N=48, Active, not recruiting, National University Hospital, Singapore | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Sep 2024

To our knowledge, this is the first report showing the efficacy of pembrolizumab in a patient with cholangiocarcinoma harboring both HER2-positive and TMB-H.

Advanced gastric adenocarcinoma patients received β-glucan, camrelizumab, oxaliplatin, oral S-1 every 3 weeks...This preliminary study demonstrates that β-glucan plus camrelizumab and SOX chemotherapy offers favorable efficacy and a manageable safety profile in patients with advanced gastric adenocarcinoma, and further studies are needed to verify its efficacy and safety. Chinese Clinical Trials Registry, identifier ChiCTR2100044088.

P3, N=626, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial primary completion date: Dec 2024 --> May 2026

P2, N=116, Not yet recruiting, Xijing Hospital

P3, N=408, Not yet recruiting, CSPC Ouyi Pharmaceutical Co., Ltd.

The regimens with >20-fold cost of conventional chemotherapy were used as first-line chemotherapy in two-thirds of patients and more than half even in the elderly population with HER2-negative AGC. This finding is important for future health economic studies on drug cost-efficacy.

P2/3, N=81, Terminated, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=896 --> 81 | Trial completion date: Dec 2027 --> Apr 2024 | Enrolling by invitation --> Terminated | Trial primary completion date: Jul 2027 --> Apr 2024; R&d strategy adjustment

Therefore, she was switched to paclitaxel-based therapy. In November 2021, the patient was further switched to nivolumab monotherapy, but she succumbed due to DIC in March 2022. GCs with BMM are prone to DIC, and the SOX regimen, which includes S-1 with efficacy against micrometastases, may constitute a safe and effective treatment modality.

This 3-year follow-up of ATTRACTION-4 confirmed the long-term clinical benefit and manageable safety of nivolumab + chemotherapy in patients with previously untreated advanced gastric cancer.

P2, N=40, Recruiting, The First Affiliated Hospital with Nanjing Medical University